Sangivamycin is highly effective against SARS-CoV-2 in vitro and has favorable drug properties.

Autor: Bennett RP; OyaGen, Inc., Rochester, New York, USA., Postnikova EN; Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Frederick, Maryland, USA., Eaton BP; Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Frederick, Maryland, USA., Cai Y; Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Frederick, Maryland, USA., Yu S; Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Frederick, Maryland, USA., Smith CO; Center for Musculoskeletal Research, University of Rochester School of Medicine & Dentistry, Rochester, New York, USA., Liang J; Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Frederick, Maryland, USA., Zhou H; Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Frederick, Maryland, USA., Kocher GA; Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Frederick, Maryland, USA., Murphy MJ; Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Frederick, Maryland, USA., Smith HC; OyaGen, Inc., Rochester, New York, USA., Kuhn JH; Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Frederick, Maryland, USA.

Publikováno v: JCI insight [JCI Insight] 2022 Jan 11; Vol. 7 (1). Date of Electronic Publication: 2022 Jan 11.